Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 44 (TMEM44) is a multi-pass transmembrane protein in humans encoded by the TMEM44 gene, located on chromosome 3q29[1][3]. The protein has a predicted molecular weight of 47.1 kDa and is composed of 428 amino acids with seven transmembrane domains[1][3]. TMEM44 is integrated within the endoplasmic reticulum membrane, with its C-terminus orientated in the cytoplasm. Multiple splice isoforms are known, and the gene shows low-level expression across various tissues such as brain, bone, ovary, pancreas, uterus, and eye[1][3][6]. Expression has been detected in tumors including those from gastrointestinal tract, ovary, pancreas, muscle, uterus, and brain[1][6]. While the exact function is unknown, TMEM44 is predicted to have basic amino acid transporter activity and belongs to the Lysosomal/Vacuolar Amino Acid Transporter family[5][7], but this function has not been definitively confirmed. Experimentally, TMEM44 has predicted interactions with proteins like GSK3B, KAT6B, and SPAG9, but a direct signaling or disease mechanism is not established[1][3]. Currently, there are no approved drugs or selective chemical modulators for TMEM44, and it is not recognized as a direct therapeutic target in established drug discovery or clinical practice. TMEM44 is not a well-characterized therapeutic target and its direct molecular functions remain largely unknown. Some literature and databases note its predicted transporter activity; other studies have focused on related non-coding RNAs from the TMEM44 locus, but not the protein itself. TMEM44-AS1, a long non-coding RNA, is associated with cancer progression and is a potential biomarker, but this is distinct from the TMEM44 protein[2][4]. In summary, TMEM44 (Transmembrane protein 44) is a putative membrane transporter protein with unknown confirmed biological function, expressed at low levels in a range of tissues, and occasionally upregulated in tumors. It is not currently considered a validated therapeutic target due to insufficient evidence regarding its physiological or pathological roles[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 44 (TMEM44).